DR-70 immunoassay for the surveillance of hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 3, 2012, Pages 547-552

  Lin, Shan Zu ^a,b,c   Chen, Chun Chia ^a,b   Lee, Kuei Chuan ^a,b   Tseng, Chih Wei ^b,d   Lin, Hsiao Yi ^a,b   Chen, Yi Chou ^a   Lin, Han Chieh ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Taipei Veterans General Hospital Yuanshan Branch   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Alpha fetoprotein; DR 70; Fibrin fibrinogen degradation products; Hepatocellular carcinoma; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DR 70 IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 84863177389     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06896.x     Document Type: Article

References (25)

1. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 2005; 19: 3-23.
2. Poon D, Anderson BO, Chen LT etal. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009; 10: 1111-8.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
4. Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract. Res. Clin. Gastroenterol. 2005; 19: 91-9.
5. Huo TI, Huang YH, Lui WY etal. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol. Rep. 2004; 11: 543-50.
6. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin. Liver Dis. 2006; 26: 385-90.
7. Farinati F, Marino D, De Giorgio M etal. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am. J. Gastroenterol. 2006; 101: 524-32.
8. Ossowski L, Quigley JP, Kellerman GM, Reich E. Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration. J. Exp. Med. 1973; 138: 1056-64.
9. Gerner C, Steinkellner W, Holzmann K etal. Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis. Thromb. Haemost. 2001; 85: 494-501.
10. Perry R, Sheila MA, Barbara B. Elevated fibrinogen-fibrin degradation products (FDP) in serum of colorectal cancer patients. Anal. Lett. 2004; 37: 2965-76.
11. Small-Howard AL, Harris H. Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients. J. Immunoassay Immunochem. 2010; 31: 131-47.
12. Wu D, Zhou X, Yang G etal. Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. J. Immunoassay 1998; 19: 63-72.
13. Kerber A, Trojan J, Herrlinger K, Zgouras D, Caspary WF, Braden B. The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. Aliment. Pharmacol. Ther. 2004; 20: 983-7.
14. Li X, Qiao Z, Long X, Wei J, Cheng Y. Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue. Br. J. Oral. Maxillofac. Surg. 2005; 43: 513-5.
15. Manghisi G, Elba S, Mossa A etal. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
16. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19: 329-38.
17. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32-5.
18. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin. Liver Dis. 2010; 30: 3-16.
19. Chan CY, Lee SD, Wu JC etal. The diagnostic value of the assay of des-gamma-carboxy prothrombin in the detection of small hepatocellular carcinoma. J. Hepatol. 1991; 13: 21-4.
20. Huo TI, Hsia CY, Chu CJ etal. The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance. J. Surg. Oncol. 2007; 95: 645-51.
21. Lok AS, Sterling RK, Everhart JE etal. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
22. Durazo FA, Blatt LM, Corey WG etal. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2008; 23: 1541-8.
23. Marrero JA, Feng Z, Wang Y etal. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-8.
24. Torzilli G, Minagawa M, Takayama T etal. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999; 30: 889-93.
25. Levy AE, Kowdley KV. Unresectable hepatocellular carcinoma: the need for an individualized multidisciplinary approach. J. Clin. Gastroenterol. 2001; 33: 180-2.